ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Lamotrigine

Also written as “lamotrigine”, “Lamotrigine Tablets 25 mg” and “Lamictal”.

Its studies are mostly in Epilepsy · Bipolar Disorder · Epilepsy, Tonic-Clonic · Epilepsies, Partial · Schizophrenia, led by 9 companies.

Drug pageLamotrigine: every studyMany companies study it; this page follows only the 54 they lead. All 137 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Aug 14, 200254 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only330 open or runningphase 4since Aug 14, 2002Aug 14, 2002none ahead
Dr. Reddy's Laboratories80 open or runningphase 1since May 26, 2010May 26, 2010none ahead
Teva Pharmaceutical Industriesits history only40 open or runningphase 1since Jan 30, 2009Jan 30, 2009none ahead
IPCA Laboratoriesits history only20 open or runningphase 1since Jun 11, 2012Jun 11, 2012none ahead
Torrent Pharmaceuticalsits history only20 open or runningphase 1since Jul 13, 2009Jul 13, 2009none ahead
Viatrisits history only20 open or runningphase 1since Mar 30, 2008Mar 30, 2008none ahead
Alembic Pharmaceuticalsits history only10 open or runningphase 1since Jan 9, 2018Jan 9, 2018none ahead
Desitin Arzneimittelits history only10 open or runningphase 1since Dec 12, 2023Dec 12, 2023none ahead
Pharmtechnologyits history only10 open or runningphase 1since Mar 29, 2019Mar 29, 2019none ahead

Also a collaborator on its studies: BioPharma Services.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Dr. Reddy's Laboratories only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2010First studies: 2 phase 1 studies in HealthyFirst studyNCT01131975, NCT01131949
  2. Jan 17, 20122 phase 1 studies in HealthyNCT01513720, NCT01513681
  3. Jun 25, 20134 phase 1 studies in HealthyNCT01888263, NCT01888250, NCT01888757 and 1 more

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
QuinidineruleOtsukaphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 8 Dr. Reddy's Laboratories leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01888757Healthy · India1CompletedSep 201062
NCT01888731Healthy · India1CompletedAug 201062
NCT01888263Healthy · India1CompletedAug 201032
NCT01888250Healthy · India1CompletedAug 201036
NCT01513720Healthy · United States1CompletedDec 200220
NCT01513681Healthy · United States1CompletedNov 200220
NCT01131975Healthy · United States1CompletedFeb 200326
NCT01131949Healthy · United States1CompletedFeb 200326

How it is read

Names in the registry

  • “Lamotrigine”, 26 entries
  • “lamotrigine”, 12 entries
  • “Lamotrigine Tablets 25 mg”, 4 entries
  • “Lamictal”, 3 entries
  • “Lamotrigine 25 mg Chewable Tablets”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.